Results 251 to 260 of about 349,122 (350)

Prevalence and Factors Associated With Dyslipidemia Among Adults With Type 2 Diabetes: Insights From the National Health and Nutrition Examination Survey (NHANES) 2009-2018. [PDF]

Cureus
Mochu MU, Osias K, Nnorom FI, Fakoya O, Adebayo AA, Nathan-Otu E, Emanemua CE.   +6 more
europepmc   +1 more source

The Epidemiology of Aortic Aneurysms: Global and Regional Trends Between 1990 and 2021

Medicine Advances, EarlyView.
This study presents the first comprehensive global analysis of the burden and inequality of aortic aneurysm (AA) using GBD 2021 data across 204 countries and territories. While the overall global burden of AA has declined over the past three decades, our findings reveal a concerning rise in AA‐related mortality and disability‐adjusted life years (DALYs)
Jiarui Zhang, Lei Zhang, Adili Shadike, Yixian Wu, Honghao Zhu, Xinxiang Fan, Jingjun Han, Jianqiu Kong   +7 more
wiley   +1 more source

Nanoformulated Diacerein Alleviates Hyperlipidemia via Gut Microbiota Modulation In Vivo

Nano Select, EarlyView.
A nanoformulation of diacerein (Nano‐DIA) was fabricated with carboxymethyl cellulose, achieving enhanced solubility and rapid dissolution for alternative anti‐hyperlipidemia therapeutics. Mechanistic studies revealed its in vivo lipid‐lowering efficacy is through metabolite‐mediated and microbiota‐dependent manner, highlighting its dual action on host
Zheng Peng, Yi Yu, Mingyi Chen, Weibin Wu, Chunyan Zhu, Caisheng Wu, Weihua Li, Zehua Liu, Qiang Xie   +8 more
wiley   +1 more source

Occupational and lifestyle risk factors associated with metabolic fatty liver disease among university staff in Indonesia. [PDF]

Front Public Health
Husaema M, Saleh LM, Naiem MF, Wahyu A, D D.   +4 more
europepmc   +1 more source

Study of therapeutic potential of acid caffeic protocols and diabetes in mice dyslipidemia

, 2014
Vivianne Machado de Araújo
openalex   +1 more source

Fatal Pembrolizumab‐Induced Stevens‐Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Advanced Lung Adenocarcinoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
Po‐Chih Chang, Ting‐Wei Chang, Chia‐Yu Kuo, Yi‐Zhe Wu   +3 more
wiley   +1 more source

Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP‐1 Receptor Agonists: A Network Meta‐Analysis of Randomized Controlled Trials

Obesity, EarlyView.
ABSTRACT Objective This study compared the efficacy of metabolic/bariatric surgery (MBS) and GLP‐1 receptor agonists (GLP‐1 RAs), including dual GLP‐1/GIP analogues, for weight and metabolic outcomes in adults with obesity. Methods A network meta‐analysis of randomized controlled trials compared MBS or GLP‐1 RAs versus lifestyle intervention in adults ...
Lucas Sabatella, Patricia M. Ortega, Víctor Valentí Azcárate, Fernando Rotellar Sastre, Adriana Uriz Pagola, Ahmed Ahmed, Sanjay Purkayastha, Carlota Tuero Ojanguren, Nuria Blanco Asensio, Manuel F. Landecho   +9 more
wiley   +1 more source

High dyslipidemia in people living with HIV in ghana: a cross-sectional analysis of prevalence and associated factors. [PDF]

AIDS Res Ther
Abdulai K, Alhassan AR, Anane I, Addae-Mensah I, HopeSpring Harvest.   +4 more
europepmc   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

Obesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays, Phillip Toth, Naim Alkhouri, John Pullman, Bradley Freilich, Joel Neutel, Summer Ji, Scott Stubbe, Parke Hedges, Brian Lian   +9 more
wiley   +1 more source